Edition:
United States

Shire PLC (SHP.L)

SHP.L on London Stock Exchange

4,520.00GBp
27 Jun 2017
Change (% chg)

-- (--)
Prev Close
4,520.00
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
2,583,766
52-wk High
5,377.00
52-wk Low
4,056.60

SHP.L

Chart for SHP.L

About

Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company's segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas... (more)

Overall

Beta: 1.51
Market Cap(Mil.): £40,935.17
Shares Outstanding(Mil.): 907.74
Dividend: 20.64
Yield (%): --

Financials

  SHP.L Industry Sector
P/E (TTM): 92.63 14.17 19.11
EPS (TTM): 0.49 -- --
ROI: 1.42 -6.71 -5.00
ROE: 2.74 -6.16 -4.24

BRIEF-Supernus says Shire receives FDA approval for Mydayis for ADHD

* Supernus announces that its partner Shire receives FDA approval for Mydayis™ for ADHD

Jun 21 2017

Shire wins U.S. approval for long-acting ADHD drug

Shire has won U.S. approval for a long-acting attention deficit drug aimed at adolescents and adults, boosting its stock of medicines for the cognitive condition that affects millions of children and is being diagnosed more in older people.

Jun 21 2017

UPDATE 1-Shire wins U.S. approval for long-acting ADHD drug

* Shares up 1.5 percent in London trading (Adds sales forecasts, shares, reaction)

Jun 21 2017

Shire's long-acting ADHD drug wins U.S. approval

June 20 The U.S. Food and Drug Administration (FDA) on Tuesday approved Shire Plc's long-acting therapy for attention deficit hyperactivity disorder (ADHD), adding another treatment to its stock of drugs for the cognitive condition that affects millions of children.

Jun 20 2017

BRIEF-Kamada receives additional milestone payment from Shire PLC

* Kamada receives additional milestone payment under Glassia exclusive supply and distribution agreement with Shire

Jun 12 2017

BRIEF-Kamada provides update on clinical program for alpha-1 antitrypsin IV treatment

* Provides update on clinical program for alpha-1 antitrypsin IV for treatment of graft-versus-host disease

Jun 07 2017

BRIEF-Xenetic Biosciences receives update from Shire's Phase 1/2 study evaluating SHP656 in development as long-acting treatment for Hemophilia A

* Xenetic Biosciences - receives program update from partner Shire's phase 1/2 study evaluating SHP656 in development as a long-acting treatment for Hemophilia A

May 22 2017

Shire's swelling disorder drug moves closer to U.S. approval

Successful late-stage data on Shire Plc's, long-acting preventative treatment for hereditary angioedema (HAE) brings the Dublin-based drugmaker one step closer to U.S. approval, it said on Thursday.

May 18 2017

UPDATE 3-Shire's swelling disorder drug moves closer to U.S. approval

* U.S. shares rise 3.4 pct, UK stock up 1.7 pct (Adds conference call details, analyst comment; updates shares)

May 18 2017

BRIEF-Shire expects to file potential EU marketing submission for lanadelumab in H1 2018

* Shire says potential EU marketing submission for lanadelumab is expected to be filed in first half of 2018, pending discussion with the EMA

May 18 2017

More From Around the Web

Earnings vs. Estimates